20

State and federal law.

1	TO THE HOUSE OF REPRESENTATIVES:	
2	The Committee on Human Services to which was referred House Bill No.	
3	293 entitled "An act relating to health equity data reporting and registry	
4	disclosure requirements" respectfully reports that it has considered the same	
5	and recommends that the bill be amended by striking out all after the enacting	
6	clause and inserting in lieu thereof the following:	
7	* * * Health Equity Data Reporting * * *	
8	Sec. 1. 18 V.S.A. § 253 is amended to read:	
9	§ 253. DATA RESPONSIVE TO HEALTH EQUITY INQUIRIES	
10	* * *	
11	(b)(1) The Department of Health shall systematically analyze such health	
12	equity data using the smallest appropriate units of analysis feasible to detect	
13	racial and ethnic disparities, as well as disparities along the lines of primary	
14	language, sex, disability status, sexual orientation, gender identity, and	
15	socioeconomic status, and report the results of such analysis on the	
16	Department's website periodically, but not less than biannually. The	
17	Department's analysis shall be used to measure over time the impact of actions	
18	taken to reduce health disparities in Vermont. The data informing the	
19	Department's analysis shall be made available to the public in accordance with	

1	(2) Annually Every three years beginning in 2028, on or before January	
2	15, the Department shall submit a report containing the results of the analysis	
3	conducted pursuant to subdivision (1) of this subsection to the Senate	
4	Committee on Health and Welfare and to the House Committees on Health	
5	Care and on Human Services.	
6	* * * Cancer Registry Disclosure Requirements * * *	
7	Sec. 2. 18 V.S.A. § 155 is amended to read:	
8	§ 155. DISCLOSURE	
9	* * *	
10	(b) The Commissioner may furnish confidential information to the National	
11	Breast and Cervical Cancer Early Detection Program, other states' cancer	
12	registries, federal cancer control agencies, or health researchers in order to	
13	collaborate in a national cancer registry or to collaborate in cancer control and	
14	prevention research studies. However, before releasing confidential	
15	information, the Commissioner shall first obtain from such state registries,	
16	agencies, or researchers an agreement in writing to keep written assurances	
17	acceptable to the Commissioner that the identifying information shall be kept	
18	confidential and privileged as required by law. In the case of researchers, the	
19	Commissioner shall also first obtain written evidence of the approval of their	

academic committee for the protection of human subjects established in

20

1	accordance with 45 C.F.R. part 46 an institutional review board or privacy	
2	board in accordance with 45 C.F.R. § 164.512(i)(1)(i)(A) and (B).	
3	* * * Amyotrophic Lateral Sclerosis Registry Disclosure Requirements * *	
4	Sec. 3. 18 V.S.A. § 174 is amended to read:	
5	§ 174. CONFIDENTIALITY	
6	(a)(1) All identifying information regarding an individual patient or health	
7	care provider is exempt from public inspection and copying under the Public	
8	Records Act and shall be kept confidential.	
9	(2) Notwithstanding subdivision (1) of this subsection, the	
10	Commissioner may enter into data sharing and protection agreements with	
11	researchers or state, regional, or national amyotrophic lateral sclerosis	
12	registries for bidirectional data exchange, provided access under such	
13	agreements is consistent with the privacy, security, and disclosure protections	
14	in this chapter. In the case of researchers, the Commissioner shall also first	
15	obtain written evidence of the approval of their academic committee for the	
16	protection of human subjects established in accordance with 45 C.F.R. Part 46	
17	an institutional review board or privacy board in accordance with 45 C.F.R.	
18	§ 164.512(i)(1)(i)(A) and (B). The Commissioner shall disclose the minimum	
19	information necessary to accomplish a specified research purpose.	
20	* * *	

1	* * * Effective Date	e * * *
2	Sec. 4. EFFECTIVE DATE	
3	This act shall take effect on July 1, 2025.	
4		
5		
6		
7		
8		
9		
10	(Committee vote:)	
11		
12		Representative
13		FOR THE COMMITTEE